Literature DB >> 19619124

Cellular uptake of neutral phosphorodiamidate morpholino oligomers.

Patrick L Iversen1, Katherine M Aird, Rebecca Wu, Michael M Morse, Gayathri R Devi.   

Abstract

Phosphorodiamidate morpholino oligomers (PMO), which have a neutral chemistry, are extensively being used as tools for selective inhibition of gene expression in cell culture models and are currently in human clinical trials. Unlike phosphorothioates (PS ODN) and other charged oligonucleotides, little is known about the uptake characteristics of neutral oligomers. The purpose of this study was to understand the kinetics of PMO transport in cells and correlate with antisense activity. In contrast to primary cells and some transformed cell lines which were uptake permissive, established cancer cell lines showed very poor uptake with an occasional diffuse intracellular pattern. Differential PMO uptake was also observed in immune cells, with dendritic cells and monocytes showing highest uptake compared to T and B cells. In addition, PMO localization was observed to be heterogeneous within a population of uptake permissive cells. Unassisted PMO delivery targeting specific genes was correlated with functional antisense efficacy in experiments showing correction of pre-mRNA missplicing and inhibition of target enzyme activity in cells in culture. PMO internalization in uptake-permissive cells was identified to be specific, saturable, and energy-dependent, suggesting a receptor mediated uptake mechanism. Understanding PMO transport should facilitate the design of more effective synthetic antisense oligomers as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619124     DOI: 10.2174/138920109789069279

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum.

Authors:  Liutao Du; Refik Kayali; Carmen Bertoni; Francesca Fike; Hailiang Hu; Patrick L Iversen; Richard A Gatti
Journal:  Hum Mol Genet       Date:  2011-05-16       Impact factor: 6.150

Review 2.  Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.

Authors:  Liutao Du; Richard A Gatti
Journal:  J Immunol Methods       Date:  2010-12-13       Impact factor: 2.303

3.  Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.

Authors:  Yoshitsugu Aoki; Tetsuya Nagata; Toshifumi Yokota; Akinori Nakamura; Matthew J A Wood; Terence Partridge; Shin'ichi Takeda
Journal:  Hum Mol Genet       Date:  2013-07-23       Impact factor: 6.150

4.  Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers for In Situ Live-Cell Molecular Imaging of Dengue Virus Replication.

Authors:  Carla Bianca Luena Victorio; Wisna Novera; Jing Yang Tham; Satoru Watanabe; Subhash G Vasudevan; Ann-Marie Chacko
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 5.  Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era.

Authors:  Dunhui Li; Frank L Mastaglia; Sue Fletcher; Steve D Wilton
Journal:  Med Res Rev       Date:  2020-08-06       Impact factor: 12.944

6.  Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52.

Authors:  Jessica M Cale; Kane Greer; Sue Fletcher; Steve D Wilton
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.